Ethchlorvynol

Summary

Ethchlorvynol (CHEMBL591) is an approved small molecule (ATC N05CM08).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CM08
• Chemistry: 144.6 Da · C7H9ClO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL591
Name	Ethchlorvynol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5281077
ATC	N05CM08
Molecular formula	C7H9ClO
Molecular weight	144.6
InChIKey	ZEHYJZXQEQOSON-AATRIKPKSA-N

SMILES: CCC(/C=C/Cl)(C#C)O

IUPAC name: (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol

Also known as: Alvinol, Arvynol, Etclorvinol, Ethchlorvynol, Ethchlorvynol civ, Normoson, Nostel, NSC-30372, Placidyl, Roeridorm, Serenesil, Serensil

Patent coverage: 1,122 distinct patent families (4,311 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).